Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Taysha Gene Therapies, Inc.
NASDAQ:TSHAHealthcare · Biotechnology
-2.13%$4.13
AH$4.21+1.94%vs close
Mkt Cap$1.35B
Float290.51M
O/S325.83M
Vol
$ Vol
RVOL
Inst Own92.0%
SI17.6%
Earnings
Dilution
Financials Summary
Revenue$9.77M
Net Income-$109M
Total Assets$343.32M
Free Cash Flow-$93.83M
Debt & Equity
Debt 7%
Equity 93%
Total Debt$18.17M
Total Equity$246.94M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in TSHA's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$343.32M
Liabilities$96.38M
Accounts Receivable$0
Accounts Payable$6.28M
Inventory$0
PP&E (Net)$16.18M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $9.77M | $8.33M | $15.45M | $2.5M | $0 | $0 | $0 |
| YoY Growth | 17.3% | -46.1% | 517.5% | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $2.49M | $0 | $9K | $0 |
| Gross Profit | $9.77M | $8.33M | $15.45M | $15K | $0 | -$9K | $0 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 0.6% | - | - | - |
| Research and Development | $86.4M | $66M | $56.78M | $91.17M | $131.94M | $31.89M | $987K |
| Selling, General, and Administrative | $33.87M | $28.95M | $30.05M | $34.87M | $41.32M | $11.1M | $128K |
| Other | $0 | $4.84M | $1.06M | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $120.27M | $99.79M | $87.89M | $126.04M | $173.27M | $42.99M | $1.11M |
| Operating Income (EBIT) | -$110.5M | -$91.46M | -$72.44M | -$126.03M | -$173.27M | -$43M | -$1.11M |
| Operating Margin | -1130.6% | -1097.6% | -468.8% | -5037.1% | - | - | - |
| Interest Expense | $63K | $102K | $5M | $3.8M | $1.43M | $28K | $0 |
| Interest Income | $9.22M | $6.94M | $3.57M | $249K | $172K | $49K | $0 |
| Other Income (Expense) | $1.5M | $2.16M | -$39.13M | -$39.99M | -$1.26M | -$17.01M | $0 |
| Income Before Tax (EBT) | -$109M | -$89.3M | -$111.57M | -$166.01M | -$174.52M | -$60.01M | -$1.11M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$109M | -$89.3M | -$111.57M | -$166.01M | -$174.52M | -$43M | -$1.11M |
| Net Income Margin | -1115.3% | -1071.6% | -722.1% | -6635.3% | - | - | - |
| Supplementary Data | |||||||
| EPS | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 | -0.03 |
| Diluted EPS | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 | -0.03 |
| Weighted Average OS | 319.71M | 250.13M | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
| EBITDA | -$107.79M | -$87.95M | -$105.2M | -$161.04M | -$172.6M | -$59.97M | $0 |
| EBITDA Margin | -1102.9% | -1055.5% | -680.8% | -6436.6% | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $319.77M | $139.04M | $143.94M | $87.88M | $149.1M | $251.25M | $0 |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $319.77M | $139.04M | $143.94M | $87.88M | $149.1M | $251.25M | $0 |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $1.45M | $892K | $3.42M | $1.19M | $6.63M | $331K | $15K |
| Total Current Assets | $324.65M | $142.13M | $149.87M | $96.42M | $159.6M | $257.88M | $15K |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $16.18M | $15.87M | $20.41M | $25.91M | $50.61M | $287K | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $2.31M | $0 | $0 | $0 | $2.64M | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $183K | $2.37M | $2.46M | $3.95M | $1.11M | $715K | $15K |
| Total Long-Term Assets | $18.67M | $18.23M | $22.86M | $29.86M | $54.35M | $1M | $15K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | -$15K |
| Total Assets | $343.32M | $160.36M | $172.73M | $126.28M | $213.96M | $258.88M | $15K |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $6.28M | $3.59M | $6.37M | $10.95M | $21.76M | $1.99M | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $9.77M | $18.11M | $33.56M | $0 | $0 | $0 |
| Other Current Liabilities | $10.85M | $6.43M | $4.99M | $4.63M | $4.13M | $1.86M | $21K |
| Total Current Liabilities | $26.55M | $26.23M | $36.76M | $62.79M | $51.75M | $7.13M | $150K |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $18.17M | $43.94M | $40.51M | $37.97M | $37.19M | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $51.66M | $1.31M | $1.58M | $4.13M | $3.73M | $450K | $0 |
| Total Long-Term Liabilities | $69.83M | $62.61M | $61.04M | $62.54M | $66.83M | $450K | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $96.38M | $88.84M | $97.79M | $125.33M | $118.57M | $7.58M | $150K |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $3K | $2K | $2K | $1K | $0 | $0 | $0 |
| Retained Earnings | -$711.3M | -$602.3M | -$513.01M | -$401.44M | -$235.65M | -$61.13M | -$1.11M |
| Comprehensive Income & Other | -$192K | -$4.03M | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $958.24M | $673.83M | $587.94M | $402.39M | $331.03M | $312.43M | $980K |
| Total Equity | $246.94M | $71.53M | $74.94M | $949K | $95.38M | $251.3M | -$135K |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $343.32M | $160.36M | $172.73M | $126.28M | $213.96M | $258.88M | $15K |
| Supplementary Data | |||||||
| Total Debt | $18.17M | $63.18M | $61.11M | $59.93M | $63.09M | $0 | $0 |
| Net Debt | -$301.6M | -$75.86M | -$82.83M | -$27.95M | -$86.01M | -$251.25M | $0 |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$109M | -$89.3M | -$111.57M | -$166.01M | -$174.52M | -$60.01M | -$1.11M |
| Depreciation & Amortization | $1.15M | $1.25M | $1.37M | $1.17M | $492K | $9K | $4.46M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $13.3M | $13.1M | $7.91M | $18.04M | $18.18M | $3.35M | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$153K | -$2.92M | -$2.29M | -$7.8M | $14.49M | $1.96M | $0 |
| Other Working Capital | -$5.22M | -$9.55M | -$15.72M | $26.32M | $14.17M | -$2.07M | $540K |
| Total Working Capital Change | -$5.37M | -$12.47M | -$18.01M | $18.52M | $28.67M | -$111K | $540K |
| Other Non-Cash Items | $6.83M | $6.19M | $47.28M | $39.89M | $10.14M | $26.03M | -$3.75M |
| Net Cash from Operating | -$93.09M | -$81.22M | -$73.02M | -$88.39M | -$117.04M | -$30.73M | $135K |
| Investing Activities | |||||||
| Capital Expenditures | -$738K | -$374K | -$3.87M | -$24.87M | -$15.3M | -$82K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $134K | $11K | -$3.48M | -$61K | -$6.25M | -$9M | $0 |
| Net Cash from Investing | -$604K | -$363K | -$7.35M | -$24.93M | -$21.55M | -$9.08M | $0 |
| Financing Activities | |||||||
| Debt Repaid | -$9.24M | - | $3.45M | - | -$39.96M | - | - |
| Common Stock Issuance | $265.69M | $76.78M | $140.79M | $53.24M | -$360K | $165.85M | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$337K | -$96K | -$947K | -$1.15M | -$514K | $0 | $0 |
| Net Cash from Financing | $274.59M | $76.68M | $136.39M | $52.1M | $39.08M | $291.06M | $0 |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $180.9M | -$4.9M | $56.02M | -$61.22M | -$99.51M | $251.25M | $135K |
| Supplementary Data | |||||||
| Operating Cash Flow | -$93.09M | -$81.22M | -$73.02M | -$88.39M | -$117.04M | -$30.73M | $135K |
| Capital Expenditure | -$738K | -$374K | -$7.37M | -$24.87M | -$21.55M | -$9.08M | $0 |
| Free Cash Flow | -$93.83M | -$81.6M | -$80.39M | -$113.26M | -$138.6M | -$39.81M | $135K |
| Cash at Beginning | $141.64M | $146.54M | $90.52M | $151.74M | $251.25M | $0 | $0 |
| Cash at End | $322.53M | $141.64M | $146.54M | $90.52M | $151.74M | $251.25M | $135K |